Hepion Pharmaceuticals (HEPA) Stock Price, News & Analysis

Company Overview

Hepion Pharmaceuticals, Inc. is a clinical‐stage biopharmaceutical company focused on developing novel therapies for chronic liver diseases. The company harnesses epigenetic and autophagy‐modulating approaches to address high unmet medical needs in conditions such as nonalcoholic steatohepatitis (NASH), fibrosis and hepatocellular carcinoma. Hepion’s research platform is designed to identify and advance small molecules that can halt or reverse liver damage by targeting key pathways involved in inflammation, cellular stress and tissue remodeling.

The company’s lead therapeutic candidate, CRV431, is a cyclophilin inhibitor being evaluated in Phase 2 clinical trials for the treatment of NASH with bridging fibrosis. CRV431 has demonstrated the potential to reduce inflammation, fibrosis and lipid accumulation in preclinical models. In addition to CRV431, Hepion’s pipeline includes early‐stage compounds aimed at inhibiting VPS34, an enzyme involved in autophagy, which may offer complementary mechanisms to improve liver function and slow disease progression. Hepion collaborates with academic institutions and contract research organizations to advance its programs from preclinical development into human studies.

Hepion Pharmaceuticals is headquartered in the United States and conducts multi‐center trials across North America and Europe. The company is led by a management team with extensive experience in pharmaceutical development, regulatory strategy and commercialization. Hepion seeks to leverage its scientific expertise and strategic partnerships to deliver safe and effective therapies for patients suffering from chronic liver disorders.

Key Stats

• Today's Range: $0.06 to $0.06
• 50-Day Range: $0.04 to $0.08
• 52-Week Range: $0.03 to $0.08
• Volume: 45,262 shs
• Average Volume: 67,985 shs
• Market Capitalization: $729.55 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Hepion Pharmaceuticals Stock Analysis - MarketRank™

Hepion Pharmaceuticals scored higher than 18% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Hepion Pharmaceuticals.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Hepion Pharmaceuticals is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Hepion Pharmaceuticals is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Hepion Pharmaceuticals has a P/B Ratio of 0.05. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.08% of the float of Hepion Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Hepion Pharmaceuticals has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Hepion Pharmaceuticals has recently decreased by 67.68%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Hepion Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Hepion Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.08% of the float of Hepion Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Hepion Pharmaceuticals has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Hepion Pharmaceuticals has recently decreased by 67.68%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: N/A

News Sentiment

Hepion Pharmaceuticals has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Hepion Pharmaceuticals this week, compared to 0 articles on an average week.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Hepion Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 0.06% of the stock of Hepion Pharmaceuticals is held by insiders.

Percentage Held by Institutions

Only 17.24% of the stock of Hepion Pharmaceuticals is held by institutions.

HEPA Stock Analysis - Frequently Asked Questions

How have HEPA shares performed this year?

Hepion Pharmaceuticals' stock was trading at $23.5050 on January 1st, 2025. Since then, HEPA shares have decreased by 99.7% and is now trading at $0.0638.

How were Hepion Pharmaceuticals' earnings last quarter?

Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) released its quarterly earnings data on Sunday, November, 15th. The company reported ($690.00) earnings per share (EPS) for the quarter, missing the consensus estimate of ($510.00) by $180.00.

When did Hepion Pharmaceuticals' stock split?

Hepion Pharmaceuticals shares reverse split on Tuesday, March 18th 2025.The 1-50 reverse split was announced on Friday, March 14th 2025. The number of shares owned by shareholders was adjusted after the market closes on Monday, March 17th 2025. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

How do I buy shares of Hepion Pharmaceuticals?

Shares of HEPA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Hepion Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Hepion Pharmaceuticals investors own include VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE), FuelCell Energy (FCEL), NVIDIA (NVDA), Tonix Pharmaceuticals (TNXP), Advanced Micro Devices (AMD) and Meta Platforms (META).

Company Calendar

• Last Earnings: 11/15/2020
• Today: 9/18/2025
• Next Earnings (Estimated): 11/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:HEPA
• CIK: 1583771
• Web: www.hepionpharma.com
• Phone: (732) 902-4000
• Fax: 732-902-4100
• Employees: 20
• Year Founded: 2013

Profitability

• EPS (Trailing Twelve Months): ($219.00)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$48.93 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -812.56%
• Return on Assets: -207.31%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.30
• Quick Ratio: 1.30

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.29 per share
• Price / Book: 0.05

Miscellaneous

• Outstanding Shares: 11,435,000
• Free Float: 6,631,000
• Market Cap: $729.55 thousand
• Optionable: No Data
• Beta: 1.52